- Home
- / Passage Bio
Passage Bio
Stock Price
$0.6
2024-10-29
Market Capitalization
$39.4 M
2024-10-29
Passage Bio Summary
Company Summary
- Overview
- Passage Bio is a genetic medicines company developing therapies for the treatment of rare monogenic central nervous system diseases. Passage Bio develops a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using AAV technology and know-how.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- Philadelphia, PA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Alex Fotopoulos, Chief Technical Officer
James M. Wilson, Chief Scientific Advisor
Edgar B. Cale, Interim Chief Executive Officer, General Counsel and Corporate Secretary
LocationsView all
1 location detected
Philadelphia, PA HQ
United States
One Commerce Square, 2005 Market Street
Passage Bio Financials
Summary Financials
- Net income (Q1, 2026)
- ($7.6M)
- Cash (Q1, 2026)
- $33.3M
- EBIT (Q1, 2026)
- ($8.2M)
- Enterprise value
- $11.8M